Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | MET | P08581 | 7/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25278510 | 0.90 | PDGFRA (0.57) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL20032550 | 0.90 | KDR (0.52) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL25234720 | 0.85 | PDGFRA (0.51) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL25258803 | 0.85 | AXL (0.49) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL30465555 | 0.84 | PDGFRA (0.45) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL25294533 | 0.84 | PDGFRA (0.45) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL25258104 | 0.84 | PDGFRA (0.45) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL25281154 | 0.84 | PDGFRA (0.51) | KDRPDGFRAMETAXLFGFR2 | |
| SCHEMBL25233743 | 0.84 | KDR (0.48) | KDRPDGFRAMETAXL | |
| SCHEMBL30465509 | 0.84 | KDR (0.48) | KDRPDGFRAMETAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595245-B2 | Inhibitors of MET kinase | CELYN THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4448510-A1 | INHIBITORS OF MET KINASE | Kinnate Biopharma Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118742542-A | Inhibitors of MET kinase | 金耐特生物制药公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753395-B2 | Inhibitors of MET kinase | KINNATE BIOPHARMA INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230219929-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023114809-A1 | INHIBITORS OF MET KINASE | KINNATE BIOPHARMA INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595245-B2 | Inhibitors of MET kinase | MET, ABL1, ERBB2 | KDR 93/4885PDGFRA 172/4885MET 1/4885 |
| US-20230219929-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | KDR 37/4885PDGFRA 162/4885MET 1/4885 |
| US-11753395-B2 | Inhibitors of MET kinase | MET, RET, MERTK | KDR 37/4885PDGFRA 162/4885MET 1/4885 |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | KDR 37/4885PDGFRA 162/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.